HER2陰性乳がんの世界市場レポート 2025年

HER2陰性乳がん市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.9％で、238億6,000万米ドルに成長します。予測期間における成長の原動力は、アルコール消費量の増加、不健康なライフスタイルの採用、肥満の蔓延、タバコの使用量の増加、効果的な治療ソリューションに対するニーズの高まりにあるとみられます。主な動向としては、診断技術の革新、標的療法と免疫療法の統合、FDA承認、医療技術の進歩などが挙げられます。

乳がんの罹患率の増加がHER2陰性乳がん市場の成長を牽引すると予想されます。乳がんは、乳管や小葉から発生する乳房組織内の異常細胞の制御不能な増殖を特徴とする疾患です。乳がん患者数の増加には、意識の高まりや、早期かつ頻繁な発見につながるスクリーニング技術の進歩など、いくつかの要因が寄与しています。HER2陰性乳がん研究は、明確な腫瘍生物学を理解し、治療成績を改善する標的療法を開発する上で極めて重要です。例えば、2024年6月、米国の政府機関である疾病対策予防センターは、2021年に米国で新たに27万2,454人の女性が乳がんと診断され、2022年には4万2,211人が死亡したと報告しました。この有病率の増加は、効果的なHER2陰性乳がん治療に対する需要の増加を裏付けています。

HER2陰性乳がん市場の主要企業は、新しい治療を導入し、製品ラインナップを拡大し、市場での存在感を高めるために、規制当局の承認を積極的に追求しています。規制当局の承認とは、医薬品や治療が商品化前に安全性、有効性、品質基準を満たしていることを保証するために、政府機関によって与えられる正式な認可のことです。例えば、2024年10月、米国のバイオテクノロジー企業であるジェネンテック社は、PIK3CA変異を有する進行性ホルモン受容体陽性（HR+）HER2陰性乳がんの標的治療薬としてイトベビ（イナボリシブ）のFDA承認を取得しました。今回の承認により、イトベビはパルボシクリブおよびフルベストラントとの併用投与が可能となり、標準治療と比較して無増悪生存期間を有意に延長します。今回承認されたレジメンは、代替治療が限られている患者にとって極めて重要な治療選択肢を提供するものであり、本治療の恩恵を受ける可能性が最も高い患者を特定するバイオマーカー検査の重要性を浮き彫りにするものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界HER2陰性乳がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のHER2陰性乳がん市場：成長率分析
• 世界のHER2陰性乳がん市場の実績：規模と成長, 2019-2024
• 世界のHER2陰性乳がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界HER2陰性乳がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のHER2陰性乳がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• ホルモン療法
• 標的療法
• 免疫療法
• 世界のHER2陰性乳がん市場がんのステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期
• 局所進行段階
• 転移段階
• 世界のHER2陰性乳がん市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のHER2陰性乳がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン
• タキサン
• プラチナ製剤化学療法
• アルキル化剤
• 代謝拮抗剤
• 世界のHER2陰性乳がん市場ホルモン療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター（SERM）
• アロマターゼ阻害剤
• 選択的エストロゲン受容体分解薬（SERD）
• 世界のHER2陰性乳がん市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• CDK4/6阻害剤
• PI3K阻害剤
• PARP阻害剤
• 世界のHER2陰性乳がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤
• 腫瘍浸潤リンパ球（TIL）療法

第7章 地域別・国別分析

• 世界のHER2陰性乳がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のHER2陰性乳がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• HER2陰性乳がん市場：競合情勢
• HER2陰性乳がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca PLC
• Novartis International AG
• Eli Lilly and Company
• Amgen Inc.
• Daiichi Sankyo Company Limited
• Jiangsu Hansoh Pharmaceutical Co. Ltd.
• BeiGene Ltd.
• Chipscreen Biosciences Ltd.
• F. Hoffmann-La Roche Ltd
• PharmAbcine Inc.
• Adagene Inc.
• H3 Biomedicine Inc.
• Radius Health Inc.
• Zenith Epigenetics Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• HER2陰性乳がん市場2029：新たな機会を提供する国
• HER2陰性乳がん市場2029：新たな機会を提供するセグメント
• HER2陰性乳がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

HER2-negative breast cancer is a type of breast cancer in which the cancer cells do not overexpress the HER2 protein, which is responsible for promoting tumor growth. This form of cancer generally grows more slowly than HER2-positive breast cancer and is treated using targeted therapies and chemotherapy.

The primary treatment options for HER2-negative breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of powerful drugs to destroy or inhibit the growth of cancer cells by targeting rapidly dividing cells in the body. Treatment is administered at various stages, including the early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The HER2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2-negative breast cancer market statistics, including HER2-negative breast cancer industry global market size, regional shares, competitors with HER2-negative breast cancer market share, detailed HER2-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the HER2-negative breast cancer industry. This HER2-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The HER2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period was driven by the rising incidence of breast cancer, increased awareness about the disease, higher healthcare spending, an aging population, and the expansion of healthcare infrastructure.

The HER2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period is expected to be driven by rising alcohol consumption, the adoption of unhealthy lifestyles, the increasing prevalence of obesity, higher tobacco use, and the growing need for effective treatment solutions. Key trends include innovations in diagnostic technologies, the integration of targeted therapies and immunotherapies, FDA approvals, and advancements in medical technology.

The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, typically originating in the ducts or lobules. Several factors contribute to the rising number of breast cancer cases, including heightened awareness and advancements in screening technologies, which lead to earlier and more frequent detection. HER2-negative breast cancer research is critical in understanding distinct tumor biology and developing targeted therapies that improve treatment outcomes. For example, in June 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2021, 272,454 new cases of breast cancer were diagnosed among females in the United States, with 42,211 deaths recorded in 2022. This growing prevalence underscores the increasing demand for effective HER2-negative breast cancer treatments.

Leading companies in the HER2-negative breast cancer market are actively pursuing regulatory approvals to introduce new treatments, expand their product offerings, and strengthen their market presence. Regulatory approvals represent official authorizations granted by government agencies, ensuring that drugs and treatments meet safety, efficacy, and quality standards before commercialization. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval enables Itovebi to be administered in combination with palbociclib and fulvestrant, significantly enhancing progression-free survival compared to standard treatments. The newly approved regimen offers a crucial treatment option for patients with limited alternatives, highlighting the importance of biomarker testing in identifying those most likely to benefit from the therapy.

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, partnered with Pfizer Inc. to evaluate the combination of atirimociclib, Pfizer's investigational selective CDK4 inhibitor, with RLY-2608 and fulvestrant in patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. This collaboration seeks to leverage the distinct properties of both drugs to minimize off-target toxicity, which has historically limited the effectiveness of non-selective agents. Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, continues to play a key role in the development of innovative treatments for HER2-negative breast cancer.

Major players in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2-Negative Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2-negative breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2-negative breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2-negative breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Hormone Therapy; Targeted Therapy; Immunotherapy
• 2) By Cancer Stage: Early Stage; Locally Advanced Stage; Metastatic Stage
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Chemotherapy: Anthracyclines; Taxanes; Platinum-Based Chemotherapy; Alkylating Agents; Antimetabolites
• 2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Selective Estrogen Receptor Degraders (SERDs)
• 3) By Targeted Therapy: CDK4/6 Inhibitors; PI3K Inhibitors; PARP Inhibitors
• 4) By Immunotherapy: Immune Checkpoint Inhibitors; Tumor-Infiltrating Lymphocyte (TIL) Therapy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. HER2-Negative Breast Cancer Market Characteristics

3. HER2-Negative Breast Cancer Market Trends And Strategies

4. HER2-Negative Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2-Negative Breast Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global HER2-Negative Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global HER2-Negative Breast Cancer Market Growth Rate Analysis
• 5.4. Global HER2-Negative Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global HER2-Negative Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global HER2-Negative Breast Cancer Total Addressable Market (TAM)

6. HER2-Negative Breast Cancer Market Segmentation

• 6.1. Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Hormone Therapy
• Targeted Therapy
• Immunotherapy
• 6.2. Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Stage
• Locally Advanced Stage
• Metastatic Stage
• 6.3. Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracyclines
• Taxanes
• Platinum-Based Chemotherapy
• Alkylating Agents
• Antimetabolites
• 6.5. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• Selective Estrogen Receptor Degraders (SERDs)
• 6.6. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CDK4/6 Inhibitors
• PI3K Inhibitors
• PARP Inhibitors
• 6.7. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Tumor-Infiltrating Lymphocyte (TIL) Therapy

7. HER2-Negative Breast Cancer Market Regional And Country Analysis

• 7.1. Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Negative Breast Cancer Market

• 8.1. Asia-Pacific HER2-Negative Breast Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Negative Breast Cancer Market

• 9.1. China HER2-Negative Breast Cancer Market Overview
• 9.2. China HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Negative Breast Cancer Market

• 10.1. India HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Negative Breast Cancer Market

• 11.1. Japan HER2-Negative Breast Cancer Market Overview
• 11.2. Japan HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Negative Breast Cancer Market

• 12.1. Australia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Negative Breast Cancer Market

• 13.1. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Negative Breast Cancer Market

• 14.1. South Korea HER2-Negative Breast Cancer Market Overview
• 14.2. South Korea HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Negative Breast Cancer Market

• 15.1. Western Europe HER2-Negative Breast Cancer Market Overview
• 15.2. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Negative Breast Cancer Market

• 16.1. UK HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Negative Breast Cancer Market

• 17.1. Germany HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Negative Breast Cancer Market

• 18.1. France HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Negative Breast Cancer Market

• 19.1. Italy HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Negative Breast Cancer Market

• 20.1. Spain HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Negative Breast Cancer Market

• 21.1. Eastern Europe HER2-Negative Breast Cancer Market Overview
• 21.2. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Negative Breast Cancer Market

• 22.1. Russia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Negative Breast Cancer Market

• 23.1. North America HER2-Negative Breast Cancer Market Overview
• 23.2. North America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Negative Breast Cancer Market

• 24.1. USA HER2-Negative Breast Cancer Market Overview
• 24.2. USA HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Negative Breast Cancer Market

• 25.1. Canada HER2-Negative Breast Cancer Market Overview
• 25.2. Canada HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Negative Breast Cancer Market

• 26.1. South America HER2-Negative Breast Cancer Market Overview
• 26.2. South America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Negative Breast Cancer Market

• 27.1. Brazil HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Negative Breast Cancer Market

• 28.1. Middle East HER2-Negative Breast Cancer Market Overview
• 28.2. Middle East HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Negative Breast Cancer Market

• 29.1. Africa HER2-Negative Breast Cancer Market Overview
• 29.2. Africa HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Negative Breast Cancer Market Competitive Landscape And Company Profiles

• 30.1. HER2-Negative Breast Cancer Market Competitive Landscape
• 30.2. HER2-Negative Breast Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Negative Breast Cancer Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca PLC
• 31.3. Novartis International AG
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Jiangsu Hansoh Pharmaceutical Co. Ltd.
• 31.8. BeiGene Ltd.
• 31.9. Chipscreen Biosciences Ltd.
• 31.10. F. Hoffmann-La Roche Ltd
• 31.11. PharmAbcine Inc.
• 31.12. Adagene Inc.
• 31.13. H3 Biomedicine Inc.
• 31.14. Radius Health Inc.
• 31.15. Zenith Epigenetics Ltd.

32. Global HER2-Negative Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Negative Breast Cancer Market

34. Recent Developments In The HER2-Negative Breast Cancer Market

35. HER2-Negative Breast Cancer Market High Potential Countries, Segments and Strategies

• 35.1 HER2-Negative Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 HER2-Negative Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 HER2-Negative Breast Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer